CPVT has been mainly related to mutations in genes encoding the cardiac ryanodine receptor (RyR2) and cardiac calsequestrin (CASQ2), which can be identified in 60–70% of CPVT patients (Wleklinski et al., 2020). Here, CASQ2 is linked to catecholaminergic polymorphic ventricular tachycardia.